Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
An open, multicenter, phase I/II study to evaluate the safety, tolerability, and effectiveness of αPD1-MSLN-CAR T cells in patients With MSLN-positive advanced solid tumors
Advanced Solid Tumor
DRUG: αPD1-MSLN-CAR T Cells
Phase Ib: Incidence of Treatment Related adverse events (AEs), Incidence of treatment related AEs, AEs of special interest and serious adverse events(SAEs)., Up to 12 months|Phase Ib: Identification of Maximum Tolerated Dose (MTD), Incidence of dose-limiting toxicities (DLTs), day1-day28|Phase II: Objective Response Rate (ORR), as assessed by IRC, The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR) based on RECIST version 1.1., Up to 12 months
An open, multicenter, phase I/II study to evaluate the safety, tolerability, and effectiveness of αPD1-MSLN-CAR T cells in patients With MSLN-positive advanced solid tumors